Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. - Global
Retour

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

- 26 septembre 2024 - 1  mn de lecture

The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg in combination with Temozolomide in subjects with unresectable advanced neuroendocrine tumours of the lung or thymus as Disease Control Rate at 9 months.

Related Clinical Trials

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
26 septembre 2024 1  mn de lecture

Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
26 septembre 2024 1  mn de lecture

Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
Dysport® Adult Upper Limb Spasticity Extension Study
26 septembre 2024 1  mn de lecture

Dysport® Adult Upper Limb Spasticity Extension Study
Safety and Efficacy Study of Dysport RU and Glabellar Lines
26 septembre 2024 1  mn de lecture

Safety and Efficacy Study of Dysport RU and Glabellar Lines
Dysport® Adult Upper Limb Spasticity
26 septembre 2024 1  mn de lecture

Dysport® Adult Upper Limb Spasticity
Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia
26 septembre 2024 1  mn de lecture

Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical...
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
26 septembre 2024 1  mn de lecture

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
26 septembre 2024 1  mn de lecture

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
26 septembre 2024 1  mn de lecture

Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
26 septembre 2024 1  mn de lecture

Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia